Akari Therapeutics (AKTX) Net Equity Issued and Repurchased (2012 - 2025)

Akari Therapeutics (AKTX) has reported Net Equity Issued and Repurchased for 8 consecutive years, with $479560.0 the latest figure, recorded in Q4 2025.

• Quarterly Net Equity Issued and Repurchased fell 84.67% year-over-year to $479560.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.4 million (down 46.18% YoY) and the FY2025 annual result came in at $10.7 million, down 9.23% from the prior year.
• Net Equity Issued and Repurchased retreated to $479560.0 in Q4 2025 per AKTX's latest filing, from $4.8 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for AKTX reached as high as $7.1 million in Q2 2024 and fell as low as -$133000.0 in Q3 2024.
• A 4-year average of $2.8 million and a median of $1.8 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• The largest YoY upside for Net Equity Issued and Repurchased was 73.78% in 2024 against a maximum downside of 107.82% in 2024.
• Year by year, Net Equity Issued and Repurchased stood at $5.4 million in 2021, then tumbled by 66.67% to $1.8 million in 2023, then soared by 73.78% to $3.1 million in 2024, then plunged by 84.67% to $479560.0 in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $479560.0, $4.8 million, and $1.1 million for Q4 2025, Q2 2025, and Q1 2025 respectively.